Skip to main content
Qiagen N.V. logo

Qiagen N.V. — Investor Relations & Filings

Ticker · QIA ISIN · NL0015001WM6 LEI · 54930036WK3GMCN17Z57 F Manufacturing
Open in API
Filings indexed 626 across all filing types
Latest filing 2020-11-12 Regulatory Filings
Country NL Netherlands
Listing F QIA

About Qiagen N.V.

https://www.qiagen.com/

Qiagen N.V. is a global provider of "Sample to Insight" solutions, offering technologies that transform biological materials into valuable molecular insights. The company develops and markets sample and assay technologies, automated instrumentation, and bioinformatics software for molecular diagnostics, applied testing, academic research, and pharmaceutical development. Its comprehensive portfolio supports the entire workflow from sample collection and preparation of DNA, RNA, and proteins to analysis and interpretation. Key product areas include sample preparation kits, PCR, digital PCR (dPCR), and next-generation sequencing (NGS) solutions, as well as syndromic testing panels for infectious diseases.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2020-11-12 English
Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052/ Share Repurchase
Regulatory Filings
2020-11-11 English
Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052/ Share Repurchase
Regulatory Filings
2020-11-11 English
6-K
Regulatory Filings
2020-10-30 English
QIAGEN increases full-year 2020 outlook
Earnings Release Classification · 100% confidence The document is titled "Ad hoc Announcement according to Art. 17 Market Abuse Regulation" and provides an immediate update, specifically increasing the full-year 2020 outlook for net sales and adjusted EPS. It also announces that the release of full Q3 2020 results is being brought forward to the same day. This type of immediate, material financial update, often released outside of standard quarterly filing windows, is best classified as an Earnings Release (ER) as it conveys key financial performance highlights and guidance changes. Although it is an 'Ad hoc Announcement,' among the provided specific categories, 'ER' (Earnings Release) captures the essence of communicating updated financial performance expectations. Q3 2020
2020-10-28 English
QIAGEN increases full-year 2020 outlook
Earnings Release Classification · 100% confidence The document is titled "QIAGEN reports strong results for third quarter and first nine months of 2020 and increases outlook for full-year 2020". It contains detailed financial tables for Q3 2020 and the first nine months (9M) of 2020, including Net Sales, Operating Income, EPS, cash flow statements, and segment breakdowns. This structure is characteristic of a comprehensive periodic financial report covering a period shorter than a full year, which aligns with the definition of an Interim/Quarterly Report (IR). It is not an Earnings Release (ER) because it provides extensive detail beyond just highlights, and it is not a full Annual Report (10-K) as it covers only nine months. Since it contains detailed financial performance data for a specific interim period, 'IR' is the most appropriate classification. Q3 2020
2020-10-28 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.